A detailed history of Lpl Financial LLC transactions in Adaptimmune Therapeutics PLC stock. As of the latest transaction made, Lpl Financial LLC holds 183,479 shares of ADAP stock, worth $102,748. This represents 0.0% of its overall portfolio holdings.

Number of Shares
183,479
Previous 88,856 106.49%
Holding current value
$102,748
Previous $84,000 17.86%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 11, 2025

BUY
$0.54 - $0.95 $51,096 - $89,891
94,623 Added 106.49%
183,479 $99,000
Q3 2024

Nov 08, 2024

SELL
$0.92 - $1.39 $101,200 - $152,900
-110,000 Reduced 55.32%
88,856 $84,000
Q2 2024

Aug 07, 2024

BUY
$0.83 - $1.47 $74,700 - $132,300
90,000 Added 82.68%
198,856 $194,000
Q1 2024

May 10, 2024

BUY
$0.7 - $1.75 $76,199 - $190,498
108,856 New
108,856 $171,000

Others Institutions Holding ADAP

About Adaptimmune Therapeutics PLC


  • Ticker ADAP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 163,370,000
  • Market Cap $91.5M
  • Description
  • Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...
More about ADAP
Track This Portfolio

Track Lpl Financial LLC Portfolio

Follow Lpl Financial LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lpl Financial LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lpl Financial LLC with notifications on news.